Brazil and Cuba Become an Example of Cooperation in Vaccines

LATIN AMERICA AND THE CARIBBEAN, 17 May 2010

Pravda – TRANSCEND Media Service

The news is already circulating around the world of a study that researchers from five developing countries, in collaboration with the McLaughlin-Rotman Centre for Global Health of Canada (MRC) published today [13 May 2010] in the journal Nature Biotechnology, puts Brazil and Cuba as models in manufacturing low-cost drugs to poor people.

The work, the first study in large-scale “South-South” cooperation in the field of biotechnology related to health, highlights the cooperation between the BioManguinhos – a company linked to the Oswaldo Cruz Foundation in Rio and Instituto Finlay, Cuba, as a model able to save thousands of human lives. I will transcribe what Halla Torsteinsdóttir, Director of the study and member of the McLaughlin-Rotman Centre, the agency EFE said because it is very nice, we like to start the day with her:

-In 2007, there was an outbreak of meningitis in the “meningitis belt,” a band of sub-Saharan countries stretching from Senegal to Ethiopia. The World Health Organization (WHO) began seeking a company that could produce an appropriate vaccine for the epidemic.”

Thousands died and tens of thousands have been affected by the disease, which is the result of inflammation of a thin layer that surrounds the brain and spinal cord resulting from a bacterial infection. WHO determined that collaboration between the Finlay Institute, which has extensive experience in the fight against meningitis in Haiti, and the company Bio-Mangunhos, was the best option to produce a vaccine against this type of meningitis.

– Vaccines against meningitis created by large pharmaceutical companies were more complex and expensive than that derived from Brazil or Cuba, because they are designed to combat several types of meningitis. And did not cover the cepa (a specific bacteria) in Africa. The vaccine produced by Western companies is $80 per unit, while the price of those produced by the cooperation between Cuba and Brazil was less than $1.”

According to research, Brazil, China, Cuba, Egypt, India and South Africa have launched about 280 South-South partnerships for the development of medicines and treatments. The country that has the most initiatives is Brazil, with 64, followed by South Africa with 61 and Portugal with 54. Cuba has 34, seven more than China.

_________________________

Translated from Portuguese by Lisa Karpova.

© 1999-2009. «PRAVDA.Ru». When reproducing our materials in whole or in part, hyperlink to PRAVDA.Ru should be made. The opinions and views of the authors do not always coincide with the point of view of PRAVDA.Ru’s editors.

GO TO ORIGINAL – PRAVDA.RU

 

Share this article:


DISCLAIMER: The statements, views and opinions expressed in pieces republished here are solely those of the authors and do not necessarily represent those of TMS. In accordance with title 17 U.S.C. section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. TMS has no affiliation whatsoever with the originator of this article nor is TMS endorsed or sponsored by the originator. “GO TO ORIGINAL” links are provided as a convenience to our readers and allow for verification of authenticity. However, as originating pages are often updated by their originating host sites, the versions posted may not match the versions our readers view when clicking the “GO TO ORIGINAL” links. This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.


Comments are closed.